Cyclo(RGDfC)(CAS: 862772-11-0)

Cyclo(RGDfC) (CAS: 862772-11-0) is subject to various regulatory guidelines such as GHS classification for hazardous substances, REACH regulations in the EU for registration, evaluation, authorization, and restriction of chemicals, and FDA/EPA requirements for pharmaceutical and environmental safety. Ensure compliance with local and international regulations for its handling, storage, and disposal.

Alternatives to Cyclo(RGDfC) (CAS: 862772-11-0) in synthesis include other RGD peptides, such as linear RGD peptides and their analogs, which can serve as effective alternatives depending on the specific application. Common alternative reagents include Phe-Gly-Arg-Asp-NH2 and its isomers, which can be used in similar contexts.

The market and research trends for Cyclo(RGDfC) (CAS: 862772-11-0) indicate a growing interest in its use as a potent integrin αvβ3 inhibitor, particularly in anti-angiogenic therapy and targeted drug delivery. Research is also exploring its potential in tissue repair and regenerative medicine. Market trends suggest increasing demand, driven by its unique properties and expanding applications.

Waste containing Cyclo(RGDfC) (CAS: 862772-11-0) should be handled with care and disposed of according to local regulations. Collect waste in appropriate containers and ensure proper labeling. Incineration or professional waste disposal services are recommended to avoid environmental contamination. Follow all safety precautions and consult local environmental protection guidelines for disposal methods.